Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ampicillin/sulbactam · 1 trial · 1 indication
Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.
| Arm | Type | Description |
|---|---|---|
| ampicillin sodium/sulbactam sodium | EXPERIMENTAL | ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV |
| Name | Type | Description |
|---|---|---|
| ampicillin sodium/sulbactam sodium | DRUG | ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days |
Inclusion Criteria: * 16 years of age or older. * Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization. Exclusion Criteria: * Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodiu...
Ampicillin/sulbactam is an antibiotic combination being studied for the treatment of bacterial pneumonia. It pairs ampicillin, a penicillin-class antibiotic, with sulbactam, which helps preserve ampicillin's activity against certain bacteria. It is being developed by Pfizer, Inc. (ticker: PFE) and is in Phase 3 clinical development.
Ampicillin/sulbactam is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development program for this antibiotic combination.
Ampicillin/sulbactam is in Phase 3 clinical development. It is an investigational product and is not approved based on the information available. The Phase 3 trial has been completed, and no active trials are currently listed.
Ampicillin/sulbactam has been evaluated in one completed Phase 3 trial, NCT01189487, titled "The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)." The trial enrolled 47 participants in Japan, included patients aged 16 years and older of all sexes, and was uncontrolled.